Ultragenyx Pharma - RARE Net earnings per one share for the last twelve months

Ultragenyx Pharmaceutical strictly adheres to bioethical standards for material handling, maintaining a core focus on science. A team of leading geneticists develops life-saving drugs, driven by high motivation and research grants. The integration of AI and robotics in bioanalysis accelerates drug release. The annual EPS (TTM) growth rate demonstrates market trends, where the value of 12.60 reflects the metric's balance.
Financial and market metric breakdowns for Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical's monopolization of ultra-rare disease markets and premium pricing directly determine the efficiency of profit scaling. By analyzing the current EPS YoY TTM growth rate, an investor can track the trend of net income per share over a rolling year, enabling an assessment of the real return on capital and the business's resilience to market drawdowns between quarterly reports.